MX2022014247A - Biomarcadores tumorales para inmunoterapia. - Google Patents

Biomarcadores tumorales para inmunoterapia.

Info

Publication number
MX2022014247A
MX2022014247A MX2022014247A MX2022014247A MX2022014247A MX 2022014247 A MX2022014247 A MX 2022014247A MX 2022014247 A MX2022014247 A MX 2022014247A MX 2022014247 A MX2022014247 A MX 2022014247A MX 2022014247 A MX2022014247 A MX 2022014247A
Authority
MX
Mexico
Prior art keywords
icos
foxp3
biomarkers
positive
positive cells
Prior art date
Application number
MX2022014247A
Other languages
English (en)
Inventor
Cecilia Deantonio
Richard Charles Alfred Sainson
Chih-Hung Hsu
Li - Chun Lu
Lorcan Adrian Sherry
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2022014247A publication Critical patent/MX2022014247A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Biomarcadores para el pronóstico de tumores, en el carcinoma hepatocelular y otros cánceres. Medición de biomarcadores para la prescripción de inmunoterapia anticancerosa dirigida contra las células T reguladoras ICOS+ (TReg), por ejemplo, la selección de pacientes para el tratamiento con un anticuerpo anti-ICOS. Biomarcadores que comprenden: (i) relación entre el número de células ICOS FOXP3 doblemente positivas dentro de un radio de influencia definido entorno a las células ICOS simples positivas y el número total de células ICOS simples positivas, (ii) distancia media entre cada célula ICOS positiva FOXP3 negativa y su célula ICOS FOXP3 doblemente positiva más cercana, (iii) proporción de células FOXP3 positivas que son ICOS positivas, y (iv) densidad de células ICOS positivas.
MX2022014247A 2020-05-14 2021-05-13 Biomarcadores tumorales para inmunoterapia. MX2022014247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2007099.1A GB202007099D0 (en) 2020-05-14 2020-05-14 Tumour biomarkers for immunotherapy
PCT/EP2021/062778 WO2021229032A1 (en) 2020-05-14 2021-05-13 Tumour biomarkers for immunotherapy

Publications (1)

Publication Number Publication Date
MX2022014247A true MX2022014247A (es) 2022-12-02

Family

ID=71135069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014247A MX2022014247A (es) 2020-05-14 2021-05-13 Biomarcadores tumorales para inmunoterapia.

Country Status (12)

Country Link
US (1) US20230176060A1 (es)
EP (1) EP4150347A1 (es)
JP (1) JP2023526044A (es)
KR (1) KR20230009507A (es)
CN (1) CN117581101A (es)
AU (1) AU2021271120A1 (es)
BR (1) BR112022022250A2 (es)
CA (1) CA3178642A1 (es)
GB (1) GB202007099D0 (es)
IL (1) IL298164A (es)
MX (1) MX2022014247A (es)
WO (1) WO2021229032A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230044038A (ko) 2016-08-09 2023-03-31 키맵 리미티드 항-icos 항체

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1003648C2 (nl) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE59813875D1 (de) 1997-09-23 2007-02-22 Bundesrepublik Deutschland Let Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1740617B1 (en) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
RS50752B (sr) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Domeni sintetskih imunoglobulina sa svojstvima vezivanja, konstruisani u regionima molekula, koji se razlikuju od regiona, koji određuju komplementarnost
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
JP5883384B2 (ja) 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
EA027623B1 (ru) 2011-03-31 2017-08-31 Инсэрм (Инститют Насиональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Антитела, направленные против icos, и их применения
CA2841416A1 (en) 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
DE102012013637A1 (de) 2012-07-09 2014-01-09 Iwis Motorsysteme Gmbh & Co. Kg Triebstockplanetengetriebe
EP2872646B1 (en) 2012-07-12 2017-08-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
CA2881389C (en) 2012-08-06 2022-01-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for screening patients with a cancer
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
EP2738557A1 (en) * 2012-12-03 2014-06-04 Université Libre de Bruxelles Organized immune response in cancer
WO2015103037A2 (en) 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
EP3240908A2 (en) 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
PL3273992T3 (pl) 2015-03-23 2020-11-16 Jounce Therapeutics, Inc. Przeciwciała przeciwko icos
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2018097166A1 (ja) * 2016-11-24 2018-05-31 第一三共株式会社 Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
WO2018122245A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP2020525758A (ja) 2017-06-04 2020-08-27 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズＲａｐｐａｐｏｒｔ Ｆａｍｉｌｙ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｒｅｓｅａｒｃｈ ｉｎ ｔｈｅ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
WO2019222188A1 (en) 2018-05-14 2019-11-21 Jounce Therapeutics, Inc. Methods of treating cancer
US20220049010A1 (en) 2018-09-14 2022-02-17 Université de Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen

Also Published As

Publication number Publication date
US20230176060A1 (en) 2023-06-08
IL298164A (en) 2023-01-01
CA3178642A1 (en) 2021-11-18
AU2021271120A1 (en) 2023-02-02
EP4150347A1 (en) 2023-03-22
KR20230009507A (ko) 2023-01-17
WO2021229032A1 (en) 2021-11-18
CN117581101A (zh) 2024-02-20
JP2023526044A (ja) 2023-06-20
BR112022022250A2 (pt) 2022-12-27
GB202007099D0 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
Lolli et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Li et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters
Sun et al. The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore
Simonds et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
Ye et al. Circulating tumor cells were associated with the number of T lymphocyte subsets and NK cells in peripheral blood in advanced non-small-cell lung cancer
Liu et al. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II–III gastric cancer patients with adjuvant chemotherapy
Ye et al. Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level
Wen et al. Prognostic significance of preoperative circulating monocyte count in patients with breast cancer: based on a large cohort study
Eryilmaz et al. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy
Ostadrahimi et al. Effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy: A randomized double-blind placebo-controlled clinical trial
MX2022014247A (es) Biomarcadores tumorales para inmunoterapia.
Cao et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients
Na et al. Identification of 9-core immune-related genes in bladder urothelial carcinoma prognosis
Güç et al. HALP score and GNRI: Simple and easily accessible indexes for predicting prognosis in advanced stage NSCLC patients. The İzmir oncology group (IZOG) study
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
Givechian et al. An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma
Zhao et al. Long non-coding RNA PICART1 suppresses proliferation and promotes apoptosis in lung cancer cells by inhibiting JAK2/STAT3 signaling.
Lu et al. Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer
Eckstein et al. New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?
Guan et al. Influence of different age cutoff points on the prediction of prognosis of cancer patients receiving ICIs and potential mechanistic exploration
WO2020113188A3 (en) Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
Lv et al. The prognostic role of glutathione peroxidase 1 and immune infiltrates in glioma investigated using public datasets
Kim et al. Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma
Zhao et al. Prognostic value of tumor infiltration immune cells in pancreatic cancer